ArticleCancers2025
Psoas Muscle Index as an Independent Predictor of Survival in Patients with Hepatocellular Carcinoma Receiving Systemic Targeted Therapy.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- The impact of metabolic syndrome on changes in trunk muscle CSA: a 10-year longitudinal study.Journal of bone and mineral metabolism · 2026Article
- Albumin-bilirubin grade and sarcopenia as predictors of prognosis in patients with unresectable intermediate and advanced-stage hepatocellular carcinoma.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- The Prognostic Effect of Sarcopenia in Solid Cancers Treated with Immunotherapy: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Imaging-based prognostic factors in patients undergoing thermal ablation for colorectal liver metastases. A retrospective study on the role of sarcopenia parameters and tumor burden score.Radiology and oncology · 2026Article
- Association between the psoas muscle index and disease progression and mortality in testicular germ cell tumours.The Indian journal of medical research · 2026Article
- Sarcopenia and inflammatory markers in early-stage breast cancer: a retrospective case-control study of NLR, MLR, RDW-CV, and HRR in middle-aged and elderly women.Frontiers in surgery · 2026Article
- Urinary Titin as a Non-Invasive Biomarker for Sarcopenia Sex Differences in Unresectable Digestive Malignancies: A Retrospective Cohort Study.International journal of molecular sciences · 2025Article
- Postoperative Changes in Body Composition Predict Long-Term Prognosis in Patients with Gastric Cancer.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the usefulness of the psoas muscle index (PMI) as an independent predictor of survival after systemic targeted therapy initiation in patients with hepatocellular carcinoma (HCC).
methodIn total, 214 patients with HCC who underwent systemic targeted therapy at the Gifu University Hospital were enrolled. The correlation between the PMI and the skeletal muscle index (SMI) was assessed using Pearson's correlation coefficient (PCC). The Cox proportional hazards model was employed to determine whether the PMI, along with the α-fetoprotein (AFP) level and the ALBI score, influenced survival; these variables were considered time-dependent covariates. The optimal PMI cut-off value that yielded the most significant differences in survival was determined using maximally selected statistics.
resultsThe PMI was significantly correlated with the SMI (PCC = 0.38 and
conclusionsThe PMI serves as a reliable surrogate for the SMI in assessing skeletal muscle mass and predicting survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.